

FOLLOWUS
The Fifth School of Clinical Medicine, Anhui Medical University, Hefei 230000, China
Senior Department of Cardiology, The Sixth Medical Center of Chinese People's Liberation Army General Hospital, Beijing 100037, China
School of Medicine, Nankai University, Tianjin 300071, China
Chinese People's Liberation Army Medical College, Beijing 100853, China
Corresponding author. E-mail: lizongbin@301hospital.com.cn (Z.B. Li) .
Published:2026-06
Scan QR Code
Wang Qun-Yuan, Pan Cui-Ping, Zou Yu-Ting, et al. A predictive model for heart failure in patients with hypertension and persistent atrial fibrillation: A retrospective single-center study[J]. Chinese Medical Sciences Journal, 2026, 41(2): 55-61.
Wang Qun-Yuan, Pan Cui-Ping, Zou Yu-Ting, et al. A predictive model for heart failure in patients with hypertension and persistent atrial fibrillation: A retrospective single-center study[J]. Chinese Medical Sciences Journal, 2026, 41(2): 55-61. DOI: 10.1016/j.cmsj.2026.07.001.
Objective:
This study aimed to develop and validate a predictive nomogram for heart failure in patients with hypertension and persistent atrial fibrillation (HT-PeAF).
Methods:
We retrospectively analyzed clinical data from patients with HT-PeAF hospitalized at Chinese People's Liberation Army General Hospital between 2010 and 2019. Predictive variables were selected based on multivariable logistic regression analysis and clinical relevance
which were then incorporated into a clinical nomogram. Model performance was evaluated using the area under the receiver operating characteristic curve (AUC) for discrimination
the Hosmer-Lemeshow test for calibration
and decision curve analysis for clinical utility.
Results:
Of the 395 enrolled patients
151 experienced heart failure. Nine predictive variables were identified: prior catheter ablation
low-density lipoprotein cholesterol
hemoglobin
uric acid
creatinine
total bilirubin
fasting blood glucose
red blood cell distribution width
and coronary artery disease. The nomogram demonstrated good discriminative ability (AUC = 0.77
95%
CI
: 0.72-0.81)
good calibration (
P
= 0.44)
and favorable clinical utility.
Conclusion:
This accessible tool facilitates individualized risk stratification for heart failure in HT-PeAF patients
though prospective validation in multicenter Asian cohorts is warranted.
Aune D, Mahamat-Saleh Y, Kobeissi E, et al. Blood pressure, hypertension and the risk of atrial fibrillation: a systematic review and meta-analysis of cohort studies. Eur J Epidemiol . 2023;38(2):145-178. doi: 10.1007/s10654-022-00914-0 .
Gawa ł ko M, Linz D. Atrial fibrillation detection and management in hypertension. Hypertens . 2023;80(3):523-533. doi: 10.1161/HYPERTENSIONAHA.122.19459 .
Niiranen TJ, Schnabel RB, Schutte AE, et al. Hypertension and atrial fibrillation: a frontier review from the AF-SCREEN international collaboration. Circulation . 2025;151(12):863-877. doi: 10.1161/CIRCULATIONAHA.124.071047 .
Vemulapalli S, Kim S, Thomas L, et al. Blood pressure and risk for stroke or bleeding events in patients with atrial fibrillation: results from the orbit af study. JACC . 2015;65(10 Supplement):A436. doi: 10.1016/S0735-1097(15)60436-3 .
Zeng X, Yang Y. Molecular mechanisms underlying vascular remodeling in hypertension. Rev Cardiovasc Med . 2024;25(2):72. doi: 10.31083/j.rcm2502072 .
Joglar JA, Chung MK, Armbruster AL, et al. 2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation: a r eport of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. Circulation . 2024;149(1):e1-e156. doi: 10.1161/CIR.0000000000001193 .
Pinho-Gomes AC, Azevedo L, Copland E, et al. Blood pressure-lowering treatment for the prevention of cardiovascular events in patients with atrial fibrillation: an individual participant data meta-analysis. PLoS Med . 2021;18(6):e1003599. doi: 10.1371/journal.pmed.1003599 .
Wang C, Du Z, Ye N, et al. Prevalence and prognosis of atrial fibrillation in a hypertensive population: a prospective cohort study. J Clin Hypertens . 2023;25(4):335-342. doi: 10.1111/jch.14643 .
Naccache S, Ben Kilani M, Tlili R, et al. Atrial fibrillation and hypertension: state of the art. Tunis Med . 2017;95(7):455-460 .
Sidhu B, Mavilakandy A, Hull KL, et al. Atrial fibrillation and chronic kidney disease: aetiology and management. Rev Cardiovasc Med . 2024;25(4):143. doi: 10.31083/j.rcm2504143 .
Elenjickal EJ, Travlos CK, Marques P, et al. Anticoagulation in patients with chronic kidney disease. Am J Nephrol . 2024;55(2):146-164. doi: 10.1159/000535546 .
Camm AJ, et al.European Heart Rhythm Association, European Association for Cardio-Thoracic Surgery Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J . 2010;31(19):2369-2429. doi: 10.1093/eurheartj/ehq278 .
de Vos CB, Pisters R, Nieuwlaat R, et al. Progression from paroxysmal to persistent atrial fibrillation clinical correlates and prognosis. J Am Coll Cardiol . 2010;55(8):725-731. doi: 10.1016/j.jacc.2009.11.040 .
McEvoy JW, McCarthy CP, Bruno RM, et al. 2024 ESC guidelines for the management of elevated blood pressure and hypertension. Eur Heart J . 2024;45(38):3912-4018. doi: 10.1093/eurheartj/ehae178 .
Heart Failure Group of Chinese Society of Cardiology of Chinese Medical AssociationChinese Heart Failure Association of Chinese Medical Doctor Association, Editorial Board of Chinese Journal of Cardiology. Chinese guidelines for the diagnosis and treatment of heart failure 2018. Zhonghua Xin Xue Guan Bing Za Zhi . 2018;46(10):760-789. doi: 10.3760/cma.j.issn.0253-3758.2018.10.004 .
Heusch G, Libby P, Gersh B, et al. Cardiovascular remodelling in coronary artery disease and heart failure. Lancet . 2014;383(9932):1933-1943. doi: 10.1016/S0140-6736(14)60107-0 .
Zhou B, Tian R. Mitochondrial dysfunction in pathophysiology of heart failure. J Clin Invest . 2018;128(9):3716-3726. doi: 10.1172/JCI120849 .
Santulli G, Xie W, Reiken SR, et al. Mitochondrial calcium overload is a key determinant in heart failure. Proc Natl Acad Sci USA . 2015;112(36):11389-11394. doi: 10.1073/pnas.1513047112 .
Dridi H, Kushnir A, Zalk R, et al. Intracellular calcium leak in heart failure and atrial fibrillation: a unifying mechanism and therapeutic target. Nat Rev Cardiol . 2020;17( 11):732-747. doi: 10.1038/s41569-020-0394-8 .
Batta A, Hatwal J, Batta A, et al. Atrial fibrillation and coronary artery disease: an integrative review focusing on therapeutic implications of this relationship. World J Cardiol . 2023;15(5):229-243. doi: 10.4330/wjc.v15.i5.229 .
García-Escobar A, Lázaro-García R, Goicolea-Ruigómez J, et al. Red blood cell distribution width is a biomarker of red cell dysfunction associated with high systemic inflammation and a prognostic marker in heart failure and cardiovascular disease: a potential predictor of atrial fibrillation recurrence. High Blood Press Cardiovasc Prev J Ital Soc Hypertens . 2024;31(5):437-449. doi: 10.1007/s40292-024-00662-0 .
Butt JH, McDowell K, Kondo T, et al. Heart failure with preserved ejection fraction, red cell distribution width, and sacubitril/valsartan. ESC Heart Fail . 2024;11(1):65-77. doi: 10.1002/ehf2.14558 .
Bevan GH, Rana M, Al-Furaih N, et al. Anisocytosis is associated with myocardial fibrosis and exercise capacity in heart failure with preserved ejection fraction. Heart Lung J Crit Care . 2022;54:68-73. doi: 10.1016/j.hrtlng.2022.03.013 .
Ferreira JP, Lamiral Z, Bakris G, et al. Red cell distribution width in patients with diabetes and myocardial infarction: an analysis from the examine trial. Diabetes Obes Metab . 2021;23(7):1580-1587. doi: 10.1111/dom.14371 .
Vasavda C, Kothari R, Malla AP, et al. Bilirubin links heme metabolism to neuroprotection by scavenging superoxide. Cell Chem Biol . 2019;26(10):1450-1460.e7. doi: 10.1016/j.chembiol.2019.07.006 .
Punzo A, Silla A, Fogacci F, et al. Bile acids and bilirubin role in oxidative stress and inflammation in cardiovascular diseases. Dis Basel Switz . 2024;12(5):103. doi: 10.3390/diseases12050103 .
Hamilton FW, Abeysekera K, Hamilton W, et al. Effect of bilirubin and Gilbert syndrome on health: cohort analysis of observational, genetic, and mendelian randomisation associations. BMJ Med . 2023;2(1):e000467. doi: 10.1136/bmjmed-2022-000467 .
Jovanovich A, Isakova T, Block G, et al. Deoxycholic acid, a metabolite of circulating bile acids, and coronary artery vascular calcification in CKD. Am J Kidney Dis J Natl Kidney Found . 2018;71(1):27-34. doi: 10.1053/j.ajkd.2017.06.017 .
Marrouche NF, Brachmann J, Andresen D, et al. Catheter ablation for atrial fibrillation with heart failure. N Engl J Med . 2018;378(5):417-427. doi: 10.1056/NEJ-Moa1707855 .
Providencia R, Ali H, Creta A, et al. Catheter ablation for atrial fibrillation and impact on clinical outcomes. Eur Heart J Open . 2024;4(4):oeae058. doi: 10.1093/ehjopen/oeae058 .
Virk SA, Hyun K, Brieger D, et al. Prognostic benefit of catheter ablation of atrial fibrillation in heart failure: an updated meta-analysis of randomized controlled trials. J Arrhythmia . 2023;39(2):129-141. doi: 10.1002/joa3.12812 .
Holzknecht M, Reindl M, Tiller C, et al. Global longitudinal strain improves risk assessment after ST-segment elevation myocardial infarc tion: a comparative prognostic evaluation of left ventricular functional parameters. Clin Res Cardiol J Ger Card Soc . 2021;110(10):1599-1611. doi: 10.1007/s00392-021-01855-6 .
Shuvy M, Zwas DR, Keren A, et al. Value of the CHA2 DS2 -VASc score for predicting outcome in patients with heart failure. ESC Heart Fail . 2020;7(5):2553-2560. doi: 10.1002/ehf2.12831 .
Sawano M, Shiraishi Y, Kohsaka S, et al. Performance of the MAGGIC heart failure risk score and its modification with the addition of discharge natriuretic peptides. ESC Heart Fail . 2018;5(4):610-619. doi: 10.1002/ehf2.12278 .
Publicity Resources
Related Articles
Related Author
Related Institution
京公网安备11010802024621